Of these, there was a statistically significant difference in the incidence of any AE, any infection, serious infection, nasopharyngitis, upper respiratory tract infection, herpes zoster, hepatic disorder, increased CPK, neutropenia, lymphopenia, acne, malignancy other than NMSC and atopic dermatitis, upadacitinib 30 mg versus placebo. This evidence concerns the gene PIK3C2A and cancer.